Trends in BRCA Test Utilization in an Integrated Health System, 2005–2015
Authors:
Open Access
- 8 February 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 111 (8) , 795-802
Abstract
Genetic testing to determine BRCA status has been available for over two decades, but there are few population-based studies of test diffusion. We report 10-year trends in BRCAtesting in an integrated health-care system with long-standing access to genetic services. A cohort of women aged 18 years and older was created to ascertain BRCA testing (n = 295 087). Annual testing rates between 2005 and 2015 were calculated in all women with and without incident (ie, newly diagnosed) breast and ovarian cancers and in clinically eligible subgroups by family cancer history, personal cancer history, and age at diagnosis. Secular trends were assessed using Poisson regression. Women tested early (2005–2008), midway (2009–2012), and late (2013–2015) in the study period were compared in cross-sectional analyses. Between 2005 and 2015, annual testing rates increased from 0.6/1000 person-years (pys) (95% confidence interval [CI] = 0.4 to 0.7/1000 pys) to 0.8/1000 pys (95% CI = 0.6 to 1.0/1000 pys) in women without incident breast or ovarian cancers. Rates decreased from 71.5/1000 pys (95% CI = 42.4 to 120.8/1000 pys) to 44.4/1000 pys (95% CI = 35.5 to 55.6/1000 pys) in women with incident diagnoses, despite improvements in provision of timely BRCA testing during this time frame. We found no evidence of secular trends in clinically eligible subgroups including women with family history indicating increased hereditary cancer risk, but no personal cancer history. At the end of the study period, 97.0% (95% CI = 96.6% to 97.3%) of these women remained untested. Many eligible women did not receive BRCA testing despite having insurance coverage and access to specialty genetic services, underscoring challenges to primary and secondary hereditary cancer prevention.Keywords
Funding Information
- Agency for Healthcare Research and Quality (K12HS022982)
- National Institutes of Health (T32AG027677, P01CA154292, HHSN261201100031C, U54CA163303)
This publication has 33 references indexed in Scilit:
- Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2014
- Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population‐based studyCancer, 2013
- Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counselingGynecologic Oncology, 2012
- Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counselingGenetics in Medicine, 2011
- Validation of self-reported history of hysterectomy and oophorectomy among women in an integrated group practice settingMenopause, 2009
- Genetic Predisposition to Breast Cancer: Past, Present, and FutureAnnual Review of Genomics and Human Genetics, 2008
- Meta-Analysis of BRCA1 and BRCA2 PenetranceJournal of Clinical Oncology, 2007
- Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation StatementAnnals of Internal Medicine, 2005
- Evaluating Organized Breast Cancer Screening ImplementationCancer Epidemiology, Biomarkers & Prevention, 2004
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003